Concepedia

Hong Wan

HW

Statistics

Publications

38

Citations

6.1K

H-Index

29

Active since

2007

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Pfizer (United States)

Emory University

University of Bonn

University of Edinburgh

Hong Wan is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in antiviral therapy, pharmacotherapy, and virology.

ORCID

Publications per year

2007–2023

38

Publications

38

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Angélica Jayk Bernal, Monica Maria Gomes da Silva, Dany Badibanga Musungaie et al. · New England Journal of Medicine · 2021 · 1.9K citations · Full text

, , +16

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

Francisco M. Marty, Per Ljungman, Roy F. Chemaly et al. · New England Journal of Medicine · 2017 · 1.2K citations · Full text

, , +17

Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection

Martin Markowitz, Bach‐Yen Nguyen, Eduardo Gotuzzo et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2007 · 407 citations

, , +17

Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

Jeffrey L. Lennox, Edwin DeJesus, Daniel S Berger et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 228 citations

, , +17

Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients

Jürgen K. Rockstroh, Edwin DeJesus, Jeffrey L. Lennox et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2013 · 212 citations

, , +17

1–5 of 38